SPECIAL

Immune-modulating antibodies in head and neck cancer: past, present, and future

P. Szturz MD, J.B. Vermorken

What can the tumour microenvironment tell us?

C. Boeckx, E. Smits, J. Jacobs

Immune checkpoint inhibition in triple negative breast cancer: targeting Achilles’ heel?

V. Geldhof, K. Punie, H. Wildiers

BSMO Immunomanager program

S. Aspeslagh, V. Kruse, E. De Langhe, P. Jacques, O. Malaise, D. Elewaut, B. Lauwerys, R. Wittoek, Y. Piette, B. Neyns

Merkel cell carcinoma and immune Checkpoint inhibition: where do we stand now?

S. De Keukeleire, V. Kruse, S. Rottey

Immunotherapy for locally advanced unresectable non-small cell lung cancer

T. Feys